Study on Nivolumab and Tisagenlecleucel for Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia After Treatment Loss

1 1 1

What is this study about?

This clinical trial is focused on studying a type of blood cancer called Acute Lymphoblastic Leukemia (ALL) in children, adolescents, and young adults. The study involves two treatments: Nivolumab, also known by its brand name Opdivo, and Tisagenlecleucel, known as Kymriah. Nivolumab is a medication that helps the immune system attack cancer cells, while Tisagenlecleucel is a type of cell therapy that uses modified immune cells to target and destroy cancer cells.

The purpose of the study is to determine the safety and effectiveness of combining these two treatments in patients who have previously been treated with Tisagenlecleucel but have experienced a return of their leukemia. The study will explore different timing options for starting Nivolumab to find the safest and most effective approach. Participants will receive these treatments through an intravenous infusion, which means the medication is given directly into a vein.

Throughout the study, researchers will monitor participants for any side effects and assess how well the treatments are working. The study aims to improve understanding of how these treatments can be used together to help patients with relapsed or difficult-to-treat ALL. The trial will take place over several years, with regular follow-ups to track the long-term effects and benefits of the treatment combination.

1 joining the study

Upon joining the study, eligibility is confirmed based on specific criteria, including age and medical history related to acute lymphoblastic leukemia.

Informed consent is required before participation.

2 initial assessment

An initial assessment is conducted to evaluate the current health status and confirm the absence of organ dysfunction.

Life expectancy is assessed to ensure it exceeds 12 weeks.

3 treatment preparation

Preparation for treatment involves ensuring the availability of a second dose of tisagenlecleucel (Kymriah®).

The treatment plan is tailored based on the cohort classification, which depends on the patient’s disease status and previous treatment response.

4 nivolumab administration

The administration of nivolumab (Opdivo®) is scheduled at one of four possible time points: day 14, day 11, day 5, or day -1, depending on the cohort.

Nivolumab is given as an intravenous infusion, which involves delivering the medication directly into the bloodstream.

5 tisagenlecleucel reinfusion

Following nivolumab administration, tisagenlecleucel is reinfused.

This step is crucial for patients who have experienced a loss of B-cell aplasia, a condition where B cells are not present in the blood.

6 monitoring and evaluation

Patients are monitored for any limiting toxicities from the time of infusion until day 28.

Efficacy is evaluated at three months post-reinfusion, focusing on achieving minimal residual disease (MRD) negative complete remission and B-cell aplasia.

7 follow-up assessments

Regular follow-up assessments occur at one, three, six, and twelve months after reinfusion to monitor disease response and remission status.

Long-term follow-up includes evaluating overall survival and event-free survival up to two years.

8 completion of study

The study is estimated to conclude by March 15, 2027.

Final assessments will determine the long-term efficacy and safety of the treatment combination.

Who Can Join the Study?

Patients must be between 1 to 25 years old.
Must have a history of a type of blood cancer called CD19+ relapsed or refractory B-ALL. This includes any relapse after a bone marrow transplant, a second relapse or later, or if the cancer does not respond to treatment.
Must have a second dose of a treatment called tisagenlecleucel (Kymriah®) available.
For Cohort 1: Patients must have been treated with tisagenlecleucel and show an early loss of B-cell aplasia. This means having less than 10 B cells per cubic millimeter of blood or less than 3% of total lymphocytes within 6 months after treatment, while still being in complete remission (CR) with no detectable minimal residual disease (MRD).
For Cohort 2: Patients must have been treated with tisagenlecleucel and show a loss of B-cell aplasia, with detectable CD19+ ALL in the bone marrow, blood, or cerebrospinal fluid (CSF).
Patients must have a life expectancy of more than 12 weeks.
Patients older than 16 must have a Karnofsky score greater than 70, and those younger than 16 must have a Lansky score greater than 70. These scores measure the patient’s ability to perform daily activities.
Patients must not have any organ dysfunction.
Patients must have signed an informed consent form.
Patients must be affiliated with social security or have health insurance.

Who Cannot Join the Study?

Patients who are not between the ages of 1 and 25 years old.
Patients who have not been previously treated with tisagenlecleucel (Kymriah®).
Patients who do not have a demonstrated early loss of B-cell aplasia within 6 months. B-cell aplasia means a lack of B-cells, which are a type of white blood cell important for the immune system.
Patients who are not diagnosed with relapsed or refractory B-ALL. Relapsed means the cancer has returned after treatment, and refractory means the cancer does not respond to treatment.
Patients who are not able to start Nivolumab (Opdivo®) treatment at the specified time points.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Centre Hospitalier Universitaire De Bordeaux	Bordeaux	France
Centre Hospitalier Universitaire De Lille	Lille	France

Other Sites

Site Name	City	Country
Centre Hospitalier Universitaire Rouen	Rouen	France
Centre Hospitalier Universitaire De Montpellier	Montpellier	France
Centre Hospitalier Universitaire De Nantes	Nantes	France
Centre Hospitalier Lyon Sud	Pierre Benite	France
Hopital Beaujon	Clichy	France
Axnwsvygyp Pmcmsbcc Hblbmilg Do Mxkrplsuf	Marseille	France
Ciyn Dh Nhzij	Vandoeuvre Les Nancy	France
Hcalovqr Uyxqregjeaihtc Sqjscdybfq &hvdxvc Hfidbgj dd Hpqbhnfurqv	STRASBOURG, Alsace	France

Trial status

Country	Status	Recruitment Start
France	Not recruiting	15.03.2023

Trial locations

Investigated drugs:

Nivolumab (Opdivo®) is a medication used in this trial as an anti-PD1 treatment. It is designed to help the immune system recognize and attack cancer cells. In this study, it is being tested for its safety and effectiveness when combined with another treatment in young patients with a type of leukemia that has returned or not responded to previous treatments.

Tisagenlecleucel (Kymriah®) is a type of therapy known as CAR T-cell therapy. It involves modifying a patient’s own immune cells to better recognize and fight cancer cells. In this trial, it is being used in combination with Nivolumab to see if this approach can improve outcomes for patients who have experienced a loss of the therapy’s effectiveness.

Investigated diseases:

Acute lymphocytic leukaemia

Acute Lymphoblastic Leukemia – Acute Lymphoblastic Leukemia (ALL) is a type of cancer that affects the blood and bone marrow, characterized by the overproduction of immature white blood cells, known as lymphoblasts. It primarily occurs in children, adolescents, and young adults. The disease progresses rapidly, leading to symptoms such as fatigue, fever, frequent infections, and easy bruising or bleeding due to the lack of healthy blood cells. As the abnormal cells multiply, they crowd out normal cells, impairing the body’s ability to fight infections and carry oxygen. The progression of ALL can vary, but it typically requires prompt medical intervention to manage the rapid increase of leukemic cells.

Trial ID:

2024-514345-11-00

Protocol code:

APHP200132

NCT ID:

NCT05310591

Trial Phase:

Human Pharmacology (Phase I) – Other

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Nivolumab and Tisagenlecleucel for Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia After Treatment Loss

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?